Vanqua Bio

Vanqua Bio company information, Employees & Contact Information

Explore related pages

Related company profiles:

Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD).
Looking for a particular Vanqua Bio employee's phone or email?

Vanqua Bio Questions

News

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio - Biogen

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio Biogen

Biogen (NASDAQ: BIIB) secures rights to Vanqua's C5aR1; pays $70M, IND expected 2027 - Stock Titan

Biogen (NASDAQ: BIIB) secures rights to Vanqua's C5aR1; pays $70M, IND expected 2027 Stock Titan

Vanqua Bio Highlights Positive Interim Data from its Ongoing Phase 1b Clinical Trial of VQ-101, an Allosteric Activator of GCase for the Treatment of GBA-Parkinson’s and Related Disorders, at The International Congress of Parkinson’s Disease and Movement - Yahoo Finance

Vanqua Bio Highlights Positive Interim Data from its Ongoing Phase 1b Clinical Trial of VQ-101, an Allosteric Activator of GCase for the Treatment of GBA-Parkinson’s and Related Disorders, at The International Congress of Parkinson’s Disease and Movement Yahoo Finance

Vanqua Bio to Present at the AD/PD™ 2025 International Conference - GlobeNewswire

Vanqua Bio to Present at the AD/PD™ 2025 International Conference GlobeNewswire

Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion - Reuters

Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion Reuters

Vanqua’s Parkinson’s drug shows promise as company initiates Phase Ib study - Clinical Trials Arena

Vanqua’s Parkinson’s drug shows promise as company initiates Phase Ib study Clinical Trials Arena

Biogen licenses Vanqua Bio’s immune disorder drug for up to $1.06 billion - PharmaLive

Biogen licenses Vanqua Bio’s immune disorder drug for up to $1.06 billion PharmaLive

Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal - Stocktwits

Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal Stocktwits

Northwestern biotech spinout raises $45 million - Crain's Chicago Business

Northwestern biotech spinout raises $45 million Crain's Chicago Business

Biotech startup Vanqua Bio secures new funding - The Business Journals

Biotech startup Vanqua Bio secures new funding The Business Journals

Vanqua Bio snags $85M series B to vanquish Parkinson's, Gaucher, ALS and Alzheimer's - Fierce Biotech

Vanqua Bio snags $85M series B to vanquish Parkinson's, Gaucher, ALS and Alzheimer's Fierce Biotech

Vanqua Bio Announces Positive Interim Results from Phase 1 - GlobeNewswire

Vanqua Bio Announces Positive Interim Results from Phase 1 GlobeNewswire

Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases - GlobeNewswire

Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases GlobeNewswire

Top Vanqua Bio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant